Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCN RESCU: Rosuvastatin in Compensated Cirrhosis
NCT05832229Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 2023
- Primary completion
- Aug 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rosuvastatin in Cirrhosis (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Mean change in liver stiffness at 96 weeks. Started Dec 2023; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT05832229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832229.